Publications by authors named "J Miyakoshi"
Social isolation and fragmentation represent global challenges, with the former stemming from a lack of interaction and the latter from exclusive mobs-both rooted in communication issues. Addressing these challenges, the philosophical realm introduces the concept of the "mixbiotic society." In this framework, individuals with diverse freedoms and values mix together in physical proximity with diverse mingling, recognizing their respective "fundamental incapacities" and uniting in solidarity.
View Article and Find Full Text PDFArticle Synopsis
- PD-L1 expression is a key factor in predicting the success of anti-PD-1/PD-L1 treatments in advanced lung cancer, but differences in assay results can complicate evaluations.
- A study reviewed patients who had their PD-L1 status checked using two different assays and found that a significant number showed discrepancies, which correlated with lower treatment effectiveness in those receiving pembrolizumab.
- The findings suggest that differences in PD-L1 assay results may indicate a specific resistance mechanism to treatments, highlighting the potential importance of understanding these discrepancies in clinical settings.
Article Synopsis
- - Esophageal cancer (EC) ranks as the eighth most common cancer globally, with poor prognosis in advanced stages, leading to the development of multimodality treatment approaches.
- - Immunotherapy options, like nivolumab, have gained approval for treating advanced esophageal squamous cell carcinoma, particularly in patients who have not responded to platinum-based therapies.
- - Recent trials (ATTRACTION-3 and CheckMate 648) show that nivolumab, both alone and in combination with chemotherapy or other immunotherapies, improves survival rates for patients with this type of cancer.
Article Synopsis
- * Results showed high concordance in PD-L1 positivity for primary tumors (κ = 0.80) but only moderate for metastatic tumors (κ = 0.60); however, there was poor agreement between primary and metastatic tumors when using the SP142 assay (κ = -0.03).
- * Many patients who tested negative for PD-L1 in their primary tumors may still have positive results in their metastatic tumors, suggesting they could
Background: Sequential tyrosine kinase inhibitors (TKIs) following immune checkpoint inhibitors (ICIs) increases the incidence of serious adverse events (SAEs). However, the factors and the types of TKIs that affect the incidence of SAEs remain unknown.
Methods: We retrospectively reviewed advanced non-small cell lung cancer (NSCLC) patients who received sequential TKIs following ICIs between November 2015 and April 2021.